Orient EuroPharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 10, 2022
Share
Orient EuroPharma Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 1,100.41 million compared to TWD 1,140.23 million a year ago. Net loss was TWD 187.49 million compared to TWD 47.12 million a year ago. Basic loss per share from continuing operations was TWD 2.16 compared to TWD 0.54 a year ago. Diluted loss per share from continuing operations was TWD 2.16 compared to TWD 0.54 a year ago. Basic loss per share was TWD 2.16 compared to TWD 0.54 a year ago. Diluted loss per share was TWD 2.16 compared to TWD 0.54 a year ago.
For the nine months, sales was TWD 3,446.42 million compared to TWD 3,486.19 million a year ago. Net loss was TWD 261.21 million compared to TWD 47.98 million a year ago. Basic loss per share from continuing operations was TWD 3.01 compared to TWD 0.55 a year ago. Diluted loss per share from continuing operations was TWD 3.01 compared to TWD 0.55 a year ago. Basic loss per share was TWD 3.01 compared to TWD 0.55 a year ago. Diluted loss per share was TWD 3.01 compared to TWD 0.55 a year ago.
Orient Europharma Co., Ltd. is principally engaged in the manufacture and distribution of nutritious healthcare products and medical cosmetic products, as well as western drugs. The Company operates nutritious healthcare products and medical cosmetic products segment, providing infant milk powders, nutritious products and functional healthcare products, as well as dermatological preparations, medical hair care series, organic skin care series and medical make-up products, among others; western drugs segment, providing products for cardiovascular diseases, cancer, blood diseases, diabetes, central nervous system diseases and asthma, among others.